Detection Method:Sandwich
Test principle:This assay employs a two-site sandwich ELISA to quantitate PGLYRP3 in samples. An antibody specific for PGLYRP3 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyPGLYRP3 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for PGLYRP3 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of PGLYRP3 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Product Overview:PGLYRP3 contains an N-terminal signal peptide, followed by PGRP domain IV, a transmembrane segment, PGRP domains III and II, a second transmembrane segment, and PGRP domain I at the C terminus. PGRP domain IV at the N terminus and PGRP domain I at the C terminus are extracellular. PGRPI-alpha shares 33%, 43%, and 68% amino acid identity with PGRPL, PGRPS, and PGRPI-beta (PGLYRP4), respectively. PGRP domain IV in PGRPI-alpha is 96% identical to PGRPI domain IV in PGRPI-beta. RNA dot blot analysis detected strong PGRPI-alpha expression only in esophagus. Northern blot analysis detected a 2.8-kb transcript in esophagus and thymus, and PCR detected expression in esophagus, tonsils, and thymus, with much lower expression in stomach, descending colon, rectum, and brain.
